Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EDP-514 in Healthy Subjects and Antiviral Activity in Chronic Hepatitis B
NCT04008004Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of EDP-514 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety measured by adverse events up to 56 Days. Started Jun 2019; status: completed.
02
Drugs
EDP-514
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04008004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008004.